Stability of extemporaneously prepared sodium phenylbutyrate oral suspensions
- PMID: 17617502
- DOI: 10.2146/ajhp060450
Stability of extemporaneously prepared sodium phenylbutyrate oral suspensions
Abstract
Purpose: In an effort to minimize barriers to compliance and adherence and to improve the accuracy of dosage measurement, sugar-containing and sugar-free sodium phenylbutyrate suspensions were formulated, and the stability of these products over a 90-day period was determined.
Methods: An oral suspension of sodium phenylbutyrate 200 mg/mL was prepared by thoroughly grinding 12 g of Sodium Phenylbutyrate Powder, USP, in a glass mortar. Thirty milliliters of Ora-Plus and 30 mL of either Ora-Sweet or Ora-Sweet SF were mixed and added to the powder to make a final volume of 60 mL. Three identical samples of each formulation were prepared and placed in 2-oz amber plastic bottles with child-resistant caps and were stored at room temperature. A 500-microL sample was withdrawn from each of the six bottles with a micropipette immediately after preparation and at 7, 14, 28, 60, and 90 days. After further dilution to an expected concentration of 100 microg/mL with the mobile phase, the samples were assayed by high-performance liquid chromatography. Stability was defined as the retention of at least 90% of the initial concentration.
Results: At least 95% of the initial sodium phenylbutyrate concentration remained throughout the 90-day study period in both preparations. There were no detectable changes in color, odor, taste, and pH and no visible microbial growth in any sample.
Conclusion: Extemporaneously compounded suspensions of sodium phenylbutyrate, 200 mg/mL, in a 1:1 mixture of Ora-Plus and Ora-Sweet or Ora-Sweet SF were stable for at least 90 days when stored in 2-oz amber plastic bottles at room temperature.
Similar articles
-
Stability of extemporaneously prepared rifaximin oral suspensions.Am J Health Syst Pharm. 2010 Feb 15;67(4):287-9. doi: 10.2146/ajhp090206. Am J Health Syst Pharm. 2010. PMID: 20133533
-
Stability of extemporaneously prepared moxifloxacin oral suspensions.Am J Health Syst Pharm. 2009 Apr 1;66(7):665-7. doi: 10.2146/ajhp080152. Am J Health Syst Pharm. 2009. PMID: 19299374
-
Stability of extemporaneously prepared glycopyrrolate oral suspensions.Am J Health Syst Pharm. 2011 May 1;68(9):843-5. doi: 10.2146/100247. Am J Health Syst Pharm. 2011. PMID: 21515869
-
Physicochemical and Microbiological Stability of Compounded Metronidazole Suspensions in PCCA SuspendIt.Int J Pharm Compd. 2021 Mar-Apr;25(2):169-175. Int J Pharm Compd. 2021. PMID: 33798117 Free PMC article. Review.
-
Physiochemical and Microbiological Stability of Azathioprine Suspensions in PCCA Base, SuspendIt.Int J Pharm Compd. 2023 Jul-Aug;27(4):330-339. Int J Pharm Compd. 2023. PMID: 37595175 Review.
Cited by
-
An Introduction to Pharmacotherapy for Inborn Errors of Metabolism.J Pediatr Pharmacol Ther. 2018 Nov-Dec;23(6):432-446. doi: 10.5863/1551-6776-23.6.432. J Pediatr Pharmacol Ther. 2018. PMID: 30697128 Free PMC article. Review.
-
Development of α-Cyclodextrin-Based Orally Disintegrating Tablets for 4-Phenylbutyrate.Pharmaceutics. 2024 Jan 7;16(1):82. doi: 10.3390/pharmaceutics16010082. Pharmaceutics. 2024. PMID: 38258093 Free PMC article.
-
The chemical chaperone 4-phenylbutyrate inhibits adipogenesis by modulating the unfolded protein response.J Lipid Res. 2009 Dec;50(12):2486-501. doi: 10.1194/jlr.M900216-JLR200. J Lipid Res. 2009. PMID: 19461119 Free PMC article.
-
Stability of extemporaneously prepared lansoprazole suspension at two temperatures.J Pediatr Pharmacol Ther. 2013 Apr;18(2):122-7. doi: 10.5863/1551-6776-18.2.122. J Pediatr Pharmacol Ther. 2013. PMID: 23798906 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous